AngioDynamics, Inc., headquartered in Latham, New York, specializes in developing, manufacturing, and selling medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company, which employs 815 people and went public in 2004, offers products across oncology, venous therapies, and vascular interventions.
ANGO has been in the news recently: AngioDynamics Inc reported a fourth-quarter 2024 adjusted EPS loss of $0.05, beating the consensus loss of $0.16. The company is expected to breakeven in 2027 after posting a loss of US$184m in 2024, with analysts predicting a 98% annual growth rate.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
